Arcus Biosciences, Inc
Arcus Biosciences is a global biopharmaceutical company founded in 2015, focused on developing best-in-class molecules and combination therapies for cancer. The company leverages well-characterized biologic pathways to create innovative treatments, emphasizing discovery, accelerated development, and partnerships with the cancer community to bring new medicines to patients faster. Their mission is to combine expertise in science and medicine to pursue cures for cancer.
Industries
Nr. of Employees
medium (51-250)
Arcus Biosciences, Inc
Hayward, California, United States, North America
Products
Fc-silent anti-TIGIT monoclonal antibody (investigational)
A monoclonal antibody engineered to block TIGIT while minimizing Fc-mediated effector functions, developed for combination use with other immunotherapies.
HIF-2α small-molecule inhibitor (investigational)
A small-molecule antagonist targeting HIF-2α designed to disrupt protein interactions that drive tumor growth, developed with properties suitable for combination therapy in renal cell carcinoma.
A2A/A2B adenosine receptor antagonist (investigational)
A small-molecule adenosine receptor antagonist designed to inhibit multiple adenosine receptor subtypes in the tumor microenvironment to reverse adenosine-mediated immunosuppression and enhance anti-tumor immune responses.
Additional investigational oncology candidates (antibody and small-molecule classes)
Pipeline includes biologics and small molecules such as anti-CD39 biologics, tyrosine kinase inhibitors and anti–PD-1 antibodies developed for use as backbone or combination partners in clinical studies.
Fc-silent anti-TIGIT monoclonal antibody (investigational)
A monoclonal antibody engineered to block TIGIT while minimizing Fc-mediated effector functions, developed for combination use with other immunotherapies.
HIF-2α small-molecule inhibitor (investigational)
A small-molecule antagonist targeting HIF-2α designed to disrupt protein interactions that drive tumor growth, developed with properties suitable for combination therapy in renal cell carcinoma.
A2A/A2B adenosine receptor antagonist (investigational)
A small-molecule adenosine receptor antagonist designed to inhibit multiple adenosine receptor subtypes in the tumor microenvironment to reverse adenosine-mediated immunosuppression and enhance anti-tumor immune responses.
Additional investigational oncology candidates (antibody and small-molecule classes)
Pipeline includes biologics and small molecules such as anti-CD39 biologics, tyrosine kinase inhibitors and anti–PD-1 antibodies developed for use as backbone or combination partners in clinical studies.
Services
Platform clinical trial management
Design and operate multi-arm adaptive clinical trials to evaluate multiple investigational combinations and rapidly identify signals of efficacy and safety.
Collaborative drug discovery and co-development partnerships
Partnering for discovery-to-clinic programs, including joint development of small molecules and biologics optimized for combination regimens.
Translational biomarker strategy and patient selection support
Design and implementation of biomarker-informed translational plans to guide patient selection, combination choices and endpoint selection across clinical studies.
Platform clinical trial management
Design and operate multi-arm adaptive clinical trials to evaluate multiple investigational combinations and rapidly identify signals of efficacy and safety.
Collaborative drug discovery and co-development partnerships
Partnering for discovery-to-clinic programs, including joint development of small molecules and biologics optimized for combination regimens.
Translational biomarker strategy and patient selection support
Design and implementation of biomarker-informed translational plans to guide patient selection, combination choices and endpoint selection across clinical studies.
Expertise Areas
- Combination therapy development
- Small-molecule discovery and medicinal chemistry
- Antibody therapeutic engineering and Fc modulation
- Translational medicine and biomarker-driven patient selection
Key Technologies
- Medicinal chemistry
- Antibody Fc engineering
- Adenosine pathway targeting (CD73 inhibitors, A2A/A2B antagonists)
- HIF-2α small-molecule inhibition